The high expression of ST6GalNAc IV increased disialyl-T antigens in CD162 and CD45 and inhibited NK cell activity via the binding of Siglec-7 in chronic lymphocytic leukemia B cells [86]. Here, PTPRC is linked to B-cell chronic lymphocytic leukemia.